Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M

INTEGRATED BIOPHARMA INC

2026-Q3 EPS reported -$0.05 revenue$34,076,000

Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.
Revenue $10.1M, down 27.3% from $13.9M; operating loss $1.1M vs $0.7M income.
Nine-month net loss $1.5M ($0.05 loss per share) vs net income $1.0M ($0.03 EPS).
Two largest customers in Contract Manufacturing segment represented 90% of nine-month revenue (83% prior year).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

INTEGRATED BIOPHARMA INC reported nine months ended March 31, 2026 results: revenue $34.1 million, net income net loss of $1.5 million, EPS $(0.05).

Period: nine months ended March 31, 2026
Revenue: $34.1 million
Net income: net loss of $1.5 million
EPS: $(0.05)
Result: reported results

Exact text from the filing

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2026 results: revenue $10.1 million, net income net loss of $0.8 million, EPS $(0.03).

Period: quarter ended March 31, 2026
Revenue: $10.1 million
Net income: net loss of $0.8 million
EPS: $(0.03)
Result: reported results

Exact text from the filing

BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2026. Revenue for the quarter ended March 31, 2026 was $10.1 million compared to $13.9 million for the quarter ended March 31, 2025, a decrease of $3.8 million or 27.3%. The Company had an operating loss of $1.1 million in the quarter ended March

View on SEC.gov

Browse all earnings releases →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR

accession 0001437749-26-015928

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.